Health Condition 1: null- prostate cancer patients who have failed hormonal and chemotherapy
Conditions
Interventions
Intervention1: 177Lu PSMA 617 radionuclide therapy: Radiopharmaceutical
177LuCl3 obtained from BARC
PSMA 617 obtained from ABX Germany
Intervention2: lutetium prostate specific membrane antigen radio
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Patients with histologically proven prostate cancer who have been treated by either surgery or radiotherapy and antiandrogen therapy First line or Second line therapy for CRPC given but rising PSA sPSA greater than 5ng per ml Ga68 PSMA showing sites of PSMA expressing disease Normal Kidney Function Test and Liver Function Test Karnofsky performance status greater than 60 Patients with GRF level greater than 60 ml per min
Exclusion criteria
Exclusion criteria: Negative Ga68 PSMA scan Coexisting second malignancies Patients with Hbless than 11 gm percent Platelet count less than 150000 per cumm TLC less than 4000 per cumm Serum Creatinine greater than 1.3 mg percent Anticipated life expectancy of less than 3 months Patients who refuse written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Studying the pharmacokinetics and dosimetry of 177Lu-PSMA-617 in CRPC patients.Timepoint: 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic outcome of 177 Lu-PSMA-617 in these patients would be evaluated using PSA and clinical response criteriaTimepoint: follow-up of all patients every quarterly | — |
Countries
India
Contacts
Public ContactDr C S Bal
All India Institute of Medical Sciences
Outcome results
None listed